Events

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 13th December, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)
School of Biological Sciences

Title: Success in the City
Presented by Professor Joerg Kistler, Director of the Institute for Innovation in Biotechnology, University of Auckland

Professor Joerg Kistler has long been passionate about success for the life science sector in both this city and for NZ Inc. Drawing from his experiences as Director of the University of Auckland’s School of Biological Sciences for ten years, (founding) Director of the Institute for Innovation in Biotechnology for eight years, his involvement in the life sciences industry throughput that time and his research into international best practices, Joerg will give a short presentation entitled “Innovation in the City”.

Joerg will also recognise that, after almost eight years of operation, the IIB and Bioscience Enterprise programme are now well established and it is time to introduce the new team which will take over on 1 January 2014:

  • Mark Burgess, Director IIB (jointly with his role in UniServices)
  • Stephanie Tulloch, Director Bioscience Enterprise programme (previously NZTE and consultancies)
  • Kerry Loomes, Chair Steering Committee Bioscience Enterprise

The IIB/BioEnt team will continue to have the excellent support of Stephanie Bailey who has been Joerg’s PA for the past 13 years.

Please join us for a stimulating exchange about the path to Auckland’s life sciences successful future, to congratulate the MBioEnt 2013 graduates and to welcome the new IIB/BioEnt team.

All welcome. RSVPs to Margot Bethell for organisational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 18th October, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)
School of Biological Sciences

Title: Innovation Through Callaghan
Presented by Dr Mary Quin, CEO of Callaghan Innovation and Toby Littin, Acting Regional Manager, Auckland, for Callaghan Innovation

We are confident that this month’s speakers will be of great interest to companies and organisations throughout the bioscience sector. We are delighted to welcome Dr Mary Quin, CEO of Callaghan Innovation and Toby Littin, Acting Regional Manager, Auckland, for Callaghan Innovation.

You have probably realised that Callaghan Innovation is much more than IRL by a different name, but may be unsure as to its actual role and its potential impact on your company and/or research programme. CI’s stated mission is to accelerate the commercialisation of innovation by firms in New Zealand and its top ten outcomes include delivering a portfolio of Accelerator Services ….assist firms with identifying the issues constraining their growth …..(assist firms with)developing growth strategies…evaluating firms eligibility for R&D grants and administrating grants provided.

Many of you will be aware that Mary has recently returned to New Zealand to take up the position as CEO of Callaghan Innovation after 20 years working overseas in senior executive roles in NASDAQ-listed companies such as Eastman Kodak Company and Xerox. The role includes the rather daunting challenge to build an integrated and responsive organisation that will ‘unlock the potential of New Zealand’s High Value Manufacturing and Services sector and businesses through increased commercialisation of research including science, engineering, technology and design led innovation’.

At the October forum, Mary will discuss her vision for Callaghan Innovation, including the policies and services that will be provided to facilitate commercialisation success for NZ companies. Her presentation will be followed by Toby who will focus on the allocation of the $141M p.a. in grants that CI will administer over the next three years.

All welcome. RSVPs to Margot Bethell for organisational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 13 September, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)
School of Biological Sciences

Title: Revolution Unlimited
Presented by Iain Hosie, co-founder and Chief Technical Officer of Revolution Fibre

Pause for a moment to consider the possibilities of material produced by Revolution Fibre – a non-woven nanofibre substrate made from a continuous carbon polymer as fine as 1000th the width of a human hair, made without high pressures, without high temperatures …………

Nature, of course, exploits nanofibres to provide features varying from the grip of a gecko’s feet to the five-times-greater- than-steel strength of spider webs. However, attempts to mimic nature have been limited due to low outputs and techniques requiring high levels of heat and/or temperature destroying many potential properties.

Iain Hosie, co-founder and Chief Technical Officer of Revolution Fibre, will explain how they have overcome these production barriers. He will expand on the significance of the incredibly high surface area, the high porosity and permeability and the optical and electrical properties of the substrate they produce. The resulting material may, indeed, revolutionise many industries!

Revolution Fibre’s proprietary sonic electrospinning technology produces a ‘fabric’ so fine that it is only 0.05 grams – yes, grams – per square metre. The technology can use almost any carbon polymer as a base while also allowing ‘additives’ such as enzymes and plane extracts to retain their functionality. Furthermore, with production of fabric up to two meters wide and at a rate of up to 1000 square metres per hour, Revolution Fibre allows commercially viable scale-up of nanofibre products.

Revolution Fibre’s first products include cosmetic and skin rejuvenation fabrics made from collagen, composite reinforcement materials and biodegradable air filters. Future possibilities in the bioindustry include drug delivery materials, bone regeneration and biomarker detecting membranes.

Please join us as Iain Hosie explains how Revolution Fibre has taken nanofibres out of the laboratory and into the global market.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 16 August, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)
Registration: No cost, but please register by emailing director@bioscienterprise.ac.nz

Title: The Mother of Innovation
Presented by: The Honourable Ruth Richardson, former Minister of Finance from 1990 to 1993

The guest speaker for this month’s forum will be well known to most of you as a passionate and strong woman with an unwavering belief in New Zealand – and no stranger to controversy.  The Honourable Ruth Richardson established her high public profile during her time as Minister of Finance from 1990 to 1993. She was the architect of the legendary ‘Mother of All Budgets’ as well as the Fiscal Responsibility Act 1994 (the institutional framework for the conduct of fiscal policy).

Since leaving parliament in 1994, Ruth has had an extraordinarily varied and busy life advising widely on strategies to achieve the practice of good governance and the development of high quality policy frameworks. 

At this month’s forum Ruth uses her experience to look at the roles that various stakeholders have in developing New Zealand as vibrant world leaders in the life science industry. Starting with the global perspective, Ruth will then drill down to the company and researcher level, looking at how we should ‘play’ in this space.

Ruth is, or has been, chairman or director on over 20 Boards and Board committees ranging from public policy to technology to the financial sector. In the bioindustry space this includes former Chairman of ICPbio and Diary Brands Ltd, former director of Wrightson Ltd and Oyster Bay Malborough Vineyards Ltd and currently Chairman of Synlait Ltd, the Jade Software Corporation and Syft Technologies Ltd and director of Synlait Milk Ltd.

As Chairman of KiwiNet, Ruth oversees a consortium of Universities, CRIs and other publicly funded research organisations that facilitate a collaborative approach to research commercialisation through workshops, capability building and pre-seed funding. There are currently 54 projects in the Kiwinet portfolio, with a further 127 projects in the pipeline for future pre-seed investment.

Ruth has also been involved with two of a handful of NZ companies to be taken to an IPO this year (Wynyard Group and Synlait Milk Ltd). 

Please join us as The Honourable Ruth Richardson addresses the cause of “Making More from Innovation”

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz  or phone (09) 923 9625 or 0274 305 758

 Public car parking is available nearby under the U of A’s Business School, the Owen G Glenn Building, in Grafton Rd. (see attached map). There is also limited parking available in Princes St.


An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 12 July, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Is A2 for you?
Presented by A2 Corporation’s Chief Scientific Officer Dr Andrew Clarke

Rarely – never? - has a food caused so much controversy. A2 Corporation does not make any health claims about its milk – it is not even really a functional food – it excludes a protein variant that appears not to be associated with certain conditions.

A2 milk is a natural variant of ordinary milk produced by a natural genetic variant of ordinary cows. The debate about the science behind A2 can be passionate; the evidence that, for some people, ordinary milk increases the symptoms of a range of intolerance type responses and neurological conditions, coupled with linkages to a reduced risk of type 1 diabetes and heart disease this may have significant implications to subsets of populations and lead to future nutigenomic applications.

A2 Corporation’s Chief Scientific Officer Dr Andrew Clarke is an alumni of the U of A’s School of Biological Sciences. Andrew completed his PhD with Prof Garth Cooper and then joined Protemix, characterizing targets of drugs in pre-clinical trials. This was followed by two years as a consultant to both biotech start-ups and potential investors before joining A2 Corporation and publically listing the company (NZX:ATM) to aid in the commercialisation of its unique technology. We are delighted to welcome Andrew as the guest speaker at this month’s forum to discuss A2’s proprietary milk and the insights gained as A2 have commercialised their product.

Beta- casein is one of the most important proteins found milk. Genetic variation results in two main forms of this protein, known as A1 and A2. Bioactives formed during the digestion of beta- casein are important in the transport of essential ions and nutrients. However, one of the products of digestion of the A1 form is a fragment known as BCM-7. This fragment has strong opioid properties and is widely believed to have the potential to interfere with the immune system in people with particular genetic susceptibilities. It has also been shown to catalyse the formation of oxidised LDL, an established risk factor in the development of arterial problems. Current research includes establishing the molecular mechanism by which BCM-7 affects cellular inflammation, which was presented to ICFSN2013 in London earlier this week (8 July).

The A2 form does not produce BCM-7. It is this small difference that gives A2 milk, containing only the A2 form of beta-casein, its selling point. With seven patents covering the supply chain from testing through to composition and use A2 has been able to produce a highly protected brand.

Between the skeptics, legal issues and ‘learning experiences’ with licensing partners A2 has not had an easy road, even by biotech standards. However, with its seven patents behind it, plus its own manufacturing plants, plus distribution in Australia, China and the UK, plus a strong and rapidly growing market share in the specialty milk sector, the future is looking positive.

You are warmly invited to join us to hear A2 Corporation’s CSO, Dr Andrew Clarke, discuss the process of successfully developing the value of A2 milk.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 14 June, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: ‘Thank You’ From All the Fish
Presented by Photonz CSO, Dr Hywel Griffiths

While not all the many claims for the ‘wonder’ molecules in the Omega-3 family have convincing evidence, few people could doubt the impact and importance they have had on the health and wellness sector. I am sure that everyone reading this is very conscious of their weekly intake of fish and/or daily fish-oil capsule. Fish, with their relatively high proportions of the longer chained omega-3’s EPA and DHA, are consider the far superior source for these compounds. Plant oils simply cannot compete.

But fish get their omega-3’s from algae – and Photonz – the company featuring at the June forum – have gone to the source. They ferment marine microalgae to produce their fermentation product PNZ0901 and, from there, high purity EPA (eicsapentaenoic acid).

Their proprietary technology owns or controls seven patent families. Importantly, it overcomes a number of obstacles previously encountered in continuous fermentation of microalgae.

The overall process also has some huge advantages. It is….

• Sustainable; does not deplete threatened fish stocks
• Scaleable
• Able to produce a consistent, reliable supply of product
• Free from heavy metals or other contaminants and pollutants associated with fish sources
• Secure and traceable.

EPA is a critical ingredient in regulated pharmaceutical products and medicinal foods addressing cardiovascular disease. The ability of Photonz to provide a high purity and reliable source of EPA that is scaleable on demand allows them to supply drug manufacturers with confidence. Given that the global cardiovascular disease market generates annual sales in excess of USD 60 billion and as such is the world's biggest pharmaceutical segment, this is not a bad thing!

You are warmly invited to join us as Photonz CSO, Dr Hywel Griffiths talks about Photonz, from idea to implementation.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:director@bioscenterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 17 May, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: It's not a frog .......
Presented by General Manager of the Riddet Insititute, Mark Ward

.. but it is a New Zealand native. The Riddet Institute is New Zealand’s Centre of Research Excellence in an area that is increasingly credited with having one of the greatest potential impacts on NZ’s economy – the area where food meets health.

General Manager of the Riddet Insititute, Mark Ward, is the guest speaker at the next Bioscience Enterprise forum. He is passionate about now being the opportunity for many disciplines to converge – nutrition, agritech, food processing and health – to position New Zealand as the food nation for the future. ‘Future foods’, incorporating functional foods, targeted ingredients and ‘I’ (personalised) - foods, will be the key vehicle for health and wellness.

Mark’s presentation will relate global trends and demand to New Zealand’s attributes and expertise.

The Riddet Institute - bringing together leading scientists from Massey, Otago and Auckland Universities as well as Plant & Food and AgResearch – plays a pivotal role in fortifying the New Zealand food industry with scientific excellence. With more than 50 scientists plus another 50 PhDs, Riddet provides world-class competency in the areas of biomaterials science and digestive physiology relating to nutrient absorption and metabolism. Riddet’s six major areas of research range from gastrointestinal biology to modeling and engineering to innovative food solutions.

Riddet works closely with the food industry, both within NZ and internationally. Their wide-range of R&D projects have involved engaging with Fonterra, ZESPRI, Beef and Lamb NZ, PepsiCo, BASF, Yashili and DSM.

Please join us to discuss Mark Ward’s vision for the future for NZ where the bioscience disciplines converge to increase the whole value chain for health and wellness.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 19 April, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: ATEED grows weed?
Presented by Brett O’Riley, Chief Executive of ATEED (Auckland Tourism, Events and Economic Development agency)

Maybe a bit of a stretch, but I do have some Omega-3s derived from hemp at home and ATEED do want to grow Auckland’s life science industry, therefore …..?

We are delighted to welcome Brett O’Riley, Chief Executive of ATEED (Auckland Tourism, Events and Economic Development agency) as the guest speaker at the next Bioscience Enterprise forum.

ATEED has the mission to improve New Zealand’s economic prosperity by leading the successful transformation of Auckland’s economy. The restructuring that ATEED undertook late last year has included the formation of the Business Attraction and Investment Team. The Life Sciences are among the team’s main targets and supporting innovation, attracting new talent and growing investment in the region are among its principle aims.

Brett has wide experience working on change and development projects in both New Zealand and internationally. His senior management positions over the past 20 years, in both private and public sectors, include his recent role as Deputy Chief Executive, Business Innovation and Investments for the Ministry of Science and Innovation.

Please join us for Brett O’Riley’s presentation on ATEED’s plans for the business growth opportunities in the Life Sciences.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:Director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 1 March, 2013
Time: Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: Insights from Innate
Presented by Innate’s CSO, Dr Gill Webster and Business Development Manager Mr Peter Bradley

Innate Immunotherapeutics will be well known to many of you – as will the guest speakers at the first Bioscience Enterprise forum for 2013, Innate’s CSO, Dr Gill Webster and Business Development Manager Mr Peter Bradley.

Innate is a company characterised by passion; from the CSO through to the business manager, CEO and shareholders, the potential for their therapy to make a difference – a real difference – to the lives of their patients is a driving force.

Unfortunately, as we all know, passion is not enough. A strong business plan and funding are needed to support that passion – and strong science is needed to support the business plan. It is these factors that will be the focus of this month’s presentation.

Innate faces the additional challenge of introducing a treatment that is contrary to the traditional approach. Innate’s platform technology is a microparticle that stimulates the immune system and can also target specific cells after being modified by attaching selected modulators to its surface. It has wide potential applications from autoimmune and immune-sensitive diseases to infectious diseases to more effective vaccines.

The focus to date has been on secondary progressive multiple sclerosis (SPMS). People who have developed this form of MS experience the greatest degree of neurological disability and no longer go into remission. Current treatments available are based on immunosuppression . The serious negative side-effects of these drugs mean this treatment is very limited. Innate’s treatment is unique – it is both immune-enhancing and non-toxic. Results from both compassionate and phase 2a trials exceeded expectations, with patients reporting greatly improved cognitive as well as physical function.

Innate Immunotherapeutics Ltd is a public unlisted company with 1700 shareholders based mostly in NZ and the USA. The shareholders have raised over $40M for Innate’s research, with further support coming from NZTE, MSI, the MS Society (US) and Merck Serono. Innate is currently in the process of raising a further $10M for a phase 2b trial. It is planned that this drug will be acquired by one of the big pharma companies by 2015 in order to enter the $3B market and reach all people suffering from SPMS.

You are warmly invited to share Innate Immunotherapeutics insights to the importance of the science - business interface in a funding constrained environment.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email mailto:director@bioscienterprise.ac.nz or phone (09) 923 9625 or 0274 305 758.

An invitation to a University of Auckland Bioscience Enterprise Friday Forum, sponsored by NZTE

Date: Friday 7th December, 2012
Time: Networking 4:00pm, Presentation 4:30pm, followed by drinks and nibbles
Venue: SBS Reception Lounge (Common Room)

Title: On The Edge
Presented by Dave Darling, CEO of Pacific Edge

On the edge of a new year, the 2012 MBioEnt students on the edge of their professional career and Pacific Edge on the edge of……..global domination?

We are delighted that Dave Darling, CEO of Pacific Edge, will be the guest speaker for the final Bioscience Enterprise forum for 2012.

Specialising in using proteomic and genomic tools to develop technologies that allow earlier detection and monitoring of cancer, Pacific Edge not only identifies reliable biomarkers but also develops novel simple-to-use tests that have high accuracy and utility and so provide significant advances in clinical practice. They also provide the analysis for these tests through a laboratory service.

With Cxbladder on the market, Cxcolorectal in the final stages of development, a test for gastric cancer and another for melanoma in pre-clinical trials, Pacific Edge is already impacting on the field of cancer diagnosis and prognosis. They currently provide a laboratory service in New Zealand and Australia and are set to expand. Pacific Edge now has a wholly-owned subsidiary in the US – a purpose-built laboratory in Hershey, Pennsylvania with the capacity to carry out 260,000 tests for bladder cancer per year. This facility, due to be granted regulatory approval by early 2013, is intended to provide a better and more cost-effective choice to the 17,000 urologists in the US who currently spend $1 billion annually identifying bladder cancer in their patients. The fact that this facility was finished both on-schedule and within budget is certainly a positive start!

Dave joined Pacific Edge in 2003 bringing a wealth of experience in developing start-ups and early stage technologies. He has led Pacific Edge from its discovery stage through to commercialisation. While the US lab ‘going–live’ commercially in 2013 will no doubt be a wonderful 10th birthday present there have been many challenges along the way. This presentation will provide insight to some of those (sometimes unexpected) challenges.

Please join us to celebrate the end of the year and to hear CEO Dave Darling talk about Pacific Edge’s road to success.

All welcome. RSVPs to Margot Bethell for organizational purposes would be greatly appreciated. Please email director@bioscienterprise.ac.nz or phone (09) 373 7599 ext 89625 or 0274 305 758.